Catapult Therapeutics to present new CAP-100 data at the upcoming 24th European Hematological Association meeting in Amsterdam
Lelystad, The Netherlands, 22 May 2019 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, announced today that their abstract on the novel anti-CCR7 antibody CAP-100 has been accepted for an oral presentation at the 24th European Hematology Association meeting, which will take place from June 13 to 16, 2019 in Amsterdam, the Netherlands.
At the meeting Dr Carlos Cuesta-Mateos (head of preclinical research for Catapult Therapeutics) will give an oral presentation “Validation of a novel mechanism of action for treatment of CCR7+ hematological malignancies with first-in-class antibody CAP-100”, during the session “New biological and translational insights into CLL” on Saturday June 15.
“These preclinical results demonstrate the unique activity profile of CAP-100, which selectively inhibits of CCR7”, commented Dr Wim Mol, CEO of Catapult Therapeutics. “Preclinical studies have shown that our anti-CCR7 monoclonal antibody disrupts the CLL disease process at the fundamental point: inhibition of migration of tumor cells to the lymph node, thus preventing the critical escape of tumor cells to the lymph node. In addition, CAP-100 provides potent ADCC mediated tumor cell killing in the bloodstream, and it inhibits survival of tumor cells in lymphoid organs. This mechanism of action is complementary to and biologically independent from current standard of care treatments for hematological malignancies. Thus, CAP-100 is a potential mono-therapy and may also be suited for use in combination with current standard treatments.”